Waverley Pharma Inc. (WAVE.V)

0.0250 +0.0050 (+25.00%) At close: 10:09AM EDT

Waverley Pharma Inc.

4-1250 Waverley Street
Winnipeg, MB R3T 6C6
Canada
204-928-7907
https://www.waverleypharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Larry Thiessen M.B.A.	President, CEO & Director	45k	N/A	N/A
Mr. Haaris Uddin B.Com., CPA	Chief Financial Officer	85.71k	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes cancer therapeutics in the United Kingdom. It focuses on the generic oncology injectable products. The company sells generic oncology products comprising capecitabine, temozolomide, and erlotinib. Its products under development include injectable generic chemotherapy drugs, such as Pemetrexed for the treatment of non-small cell lung cancer and other indications; and Bortezomib to treat multiple myeloma and other indications. Waverley Pharma Inc. is headquartered in Winnipeg, Canada.

Corporate Governance

Waverley Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.